Tango Therapeutics, Inc. Earnings Per Share Disclosure
14. Net Loss Per Share
Basic and diluted net loss per share attributable to common stockholders was calculated as follows:
|
|
Year Ended December 31, |
|
|||||||||
|
|
(in thousands, except share and per |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Numerator: |
|
|
|
|
|
|
|
|
|
|||
Net loss |
|
$ |
(101,594 |
) |
|
$ |
(130,302 |
) |
|
$ |
(101,744 |
) |
Denominator: |
|
|
|
|
|
|
|
|
|
|||
Weighted-average common stock outstanding – basic and diluted |
|
|
116,166,187 |
|
|
|
109,226,731 |
|
|
|
94,572,448 |
|
Net loss per common share – basic and diluted |
|
$ |
(0.87 |
) |
|
$ |
(1.19 |
) |
|
$ |
(1.08 |
) |
From time to time, the Company may issue pre-funded warrants which are classified as a component of permanent equity in the Company's consolidated balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying pre-funded warrants are included in the weighted-average number of shares of common stock used to calculate basic and diluted net loss per common share immediately upon issuance because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.
In August 2023, the Company completed a private placement, in which pre-funded warrants to purchase 2,340,579 shares of common stock with an exercise price of $0.001 per share were issued. In June 2025, all of these pre-funded warrants were exercised. In October 2025, the Company completed a private placement, in which pre-funded warrants to purchase 3,226,458 shares of common stock with an exercise price of $0.001 per share were issued. All of these pre-funded warrants remain unexercised as of the December 31, 2025 balance sheet date.
The Company’s potential dilutive securities, which include common stock options and unvested restricted common stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Stock options to purchase common stock |
|
|
20,465,579 |
|
|
|
19,615,023 |
|
|
|
16,734,960 |
|
Unvested restricted common stock |
|
|
1,263,429 |
|
|
|
1,209,333 |
|
|
|
757,514 |
|
Total |
|
|
21,729,008 |
|
|
|
20,824,356 |
|
|
|
17,492,474 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 5, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
| 2023 | Mar 18, 2024 | |
| 2022 | Mar 27, 2023 | |
| 2021 | Mar 28, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.